无套内射无矿码免费看黄_亚洲精品嫩草AV在线观看_久久久久久国产精品免费免费男同_正在播放少妇呻吟对白_亚洲日韩欧美成人久久_色哟哟国产精品免费观看_4d肉蒲团之性奴大战奶水_人人妻人人澡人人爽_国产精品熟女在线视频_野外做受三级视频

加拿大Resverlogix  
Resverlogix Corp. (TSX: RVX) 是一家心血管疾病臨床研究公司，公司擁有能夠調(diào)節(jié)蛋白質(zhì)形成的表觀遺傳學(xué)平臺(tái)技術(shù)。Resverlogix 正在開發(fā) RVX-208——用于治療動(dòng)脈粥樣硬化的同類首個(gè)小分子。RVX-208 是首個(gè)正在進(jìn)行臨床試驗(yàn)的 BET 溴區(qū)結(jié)構(gòu)域抑制劑。出自 Resverlogix 表觀遺傳學(xué)藥物發(fā)現(xiàn)平臺(tái)的新復(fù)合制劑通過抑制 BET 溴區(qū)結(jié)構(gòu)域而發(fā)揮作用，并有希望用來治療癌癥、自身免疫性疾病和神經(jīng)退行性疾病等多種病癥。Resverlogix 的普通股在多倫多證券交易所交易 (TSX: RVX)。

Resverlogix Corp. is a publicly traded biotechnology company (TSX:RVX) engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas? Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and Autoimmune diseases.

Our Business Model is to seek strategic opportunities through early alliance partnerships that are best suited to bring our technology platforms to successful commercialization. We are committed to good corporate governance and protection of shareholder value.